首页> 美国卫生研究院文献>other >Improved Detection of Circulating Tumor Cells in Metastatic Colorectal Cancer by the Combination of the CellSearch® System and the AdnaTest®
【2h】

Improved Detection of Circulating Tumor Cells in Metastatic Colorectal Cancer by the Combination of the CellSearch® System and the AdnaTest®

机译:通过结合CellSearch®系统和AdnaTest®改进对转移性结直肠癌中循环肿瘤细胞的检测

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Colorectal cancer (CRC) is one of the major causes of cancer-related death and reliable blood-based prognostic biomarkers are urgently needed. The enumeration and molecular characterization of circulating tumor cells (CTCs) has gained increasing interest in clinical practice. CTC detection by CellSearch® has already been correlated to an unfavorable outcome in metastatic CRC. However, the CTC detection rate in mCRC disease is low compared to other tumor entities. Thus, the use of alternative (or supplementary) assays might help to itemize the prognostic use of CTCs as blood-based biomarkers. In this study, blood samples from 47 mCRC patients were screened for CTCs using the FDA-cleared CellSearch® technology and / or the AdnaTest®. 38 samples could be processed in parallel. We demonstrate that a combined analysis of CellSearch® and the AdnaTest® leads to an improved detection of CTCs in our mCRC patient cohort (positivity rate CellSearch® 33%, AdnaTest® 30%, combined 50%). While CTCs detected with the CellSearch® system were significantly associated with progression-free survival (p = 0.046), a significant correlation regarding overall survival could be only seen when both assays were combined (p = 0.013). These findings could help to establish improved tools to detect CTCs as on-treatment biomarkers for clinical routine in future studies.
机译:大肠癌(CRC)是与癌症相关的死亡的主要原因之一,迫切需要可靠的基于血液的预后生物标记物。循环肿瘤细胞(CTC)的枚举和分子表征已在临床实践中引起越来越多的兴趣。 CellSearch ®进行的CTC检测已经与转移性CRC的不良结果相关联。但是,与其他肿瘤实体相比,mCRC疾病中的CTC检测率很低。因此,使用替代(或补充)测定可能有助于逐项列出CTC作为基于血液的生物标志物的预后使用。在这项研究中,使用FDA批准的CellSearch ®技术和/或AdnaTest ®对47名mCRC患者的血液样本进行了CTC筛选。 38个样本可以并行处理。我们证明,对CellSearch ®和AdnaTest ®的组合分析可改善mCRC患者队列中CTC的检测(阳性率CellSearch ® 33%,AdnaTest ® 30%,合计50%)。虽然使用CellSearch ®系统检测到的CTC与无进展生存期显着相关(p = 0.046),但只有将两种测定法组合使用时,才可以看到与总体生存率显着相关(p = 0.013)。这些发现可能有助于建立改进的工具来检测CTC,将其作为治疗上的生物标记物,用于将来的临床研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号